TransMed7

What TransMed7 does

TransMed7, LLC is a privately-held medical technology company founded in 2010 and headquartered in the United States, focused on developing minimally invasive medical devices for biopsy, soft tissue surgery, cardiovascular intervention, and endoscopic applications. The company's core asset is Zero5, a patented and FDA-cleared rotating beak design technology that the company describes as offering five critical advantages over traditional side-cutting biopsy devices: zero dead space, zero collateral tissue displacement, zero limitations on sample length, zero restrictions on tissue density, and zero sample structure distortion. Zero5 enables Single Insertion-Multiple Collection (SIMC) workflows and serves as the platform architecture for a portfolio of named devices including SpeedBird and Concorde (breast health biopsy), Cardinal (fine needle core biopsy), Heron (prostate, liver, kidney), Martinet (whole mass excision), Corsair (vascular atherectomy), Phoenix (flexible microcatheter endoscopy), and ThunderBird (laparoscopic/thoracoscopic), supported by VacuPac and VacuTower vacuum assist accessories. The IP estate comprises 13+ granted US patents, multiple granted international patents, and 36 pending applications across next-generation devices.

The company structures its development and commercialization through wholly-owned project companies, including Heron MD, LLC (prostate/liver/kidney biopsy focus, established November 2019) and TransVascular Dynamics, Inc. (cardiovascular intervention, anchored by the Corsair platform). TransMed7 operates in a pre-commercial stage and explicitly states that no devices are currently for sale, with future revenue intended to come from direct hardware sales of medical devices to hospitals, clinics, and ambulatory surgical centers. Distribution channels are described as global in intent, though the website is currently restricted to US users. The company has engaged Wilson Sonsini Goodrich & Rosati as strategic legal counsel and has appointed an interventional cardiology pioneer (Dr. John B. Simpson) as a strategic advisor, signaling preparation for future equity transactions or M&A. Headcount is reported at 11–50 employees and the company maintains an active web and social media presence but has no disclosed funding rounds, revenue figures, or institutional investors.

Name

TransMed7

Legal name

TransMed7, LLC

Website

https://transmed7.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

TransMed7 is a privately-held medical technology company developing FDA-cleared Zero5 rotating beak technology applied across multiple minimally invasive biopsy and intervention platforms serving breast health, urology, cardiovascular, and endoscopic applications. Currently pre-commercial with no devices on the market.

Ownership category

akta.pro rank

Product category

Biopsy and Minimally Invasive Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)

Keywords

• Minimally invasive biopsy devices
• Forward-coring biopsy technology
• Breast biopsy equipment
• Soft tissue biopsy instruments
• Medical device technology

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: TransMed7 is currently in pre-commercial development stage with no devices currently for sale. The company develops medical devices across multiple platforms for biopsy, cardiovascular intervention, and soft tissue procedures. Revenue will be generated through device sales when products reach commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TransMed7 develops and manufactures minimally invasive medical devices built on its patented Zero5 rotating beak technology platform for biopsy and cardiovascular intervention applications. The company offers a portfolio of specialized device platforms (SpeedBird, Concorde, Cardinal, Heron, Martinet, Corsair, Phoenix, ThunderBird) and accessories (VacuPac, VacuTower) targeting breast health, prostate, liver, kidney, vascular, laparoscopic, thoracoscopic, and endoscopic procedures. The company is currently in pre-commercial stage with no devices currently for sale.

Product overview

TransMed7 is a privately-held medical technology company founded in 2010 that has developed Zero5, a patented and FDA-cleared rotating beak technology platform. The company's product portfolio centers on the Zero5 technology applied across multiple specialized biopsy and intervention devices: SpeedBird and Concorde for breast health (ultrasound and stereotactic-guided biopsy); Cardinal for fine needle core biopsy of small tissues; Heron for prostate, liver, and kidney procedures; Martinet for whole mass removal; Phoenix for flexible endoscopic applications; and ThunderBird for laparoscopic/thoracoscopic procedures. The ecosystem is supported by VacuPac and VacuTower vacuum assist and cytology capture accessories. For cardiovascular intervention, the Corsair platform serves as the baseline technology for TransVascular Dynamics. All devices share the core Zero5 technology characteristics of zero dead space, zero collateral tissue damage, and single insertion-multiple collection (SIMC) capability.

Differentiator

Problem solved

Functional benefit

Brands

• Zero5: Patented and FDA-cleared rotating beak design technology platform for biopsy procedures with 5 critical advantages: zero dead space, zero collateral tissue displacement, zero limitations on sample length, zero restrictions on tissue density, and zero sample structure distortion.
• SpeedBird
• Concorde
• Cardinal
• VacuPac
• VacuTower
• ThunderBird
• Phoenix
• Heron
• Martinet
• Corsair

Products and services

• Zero5 Technology Platform
• SpeedBird
• Concorde
• Cardinal
• Heron
• VacuPac
• VacuTower
• Martinet
• Corsair
• Phoenix
• ThunderBird
• Colibri

Quantifiable outcome

• Single Insertion-Multiple Collection (SIMC) replaces traditional single insertion/single sample devices
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Two partnerships are on record, tiered core.

• Wilson Sonsini Goodrich and RosaticoreImplementation/ SI/ Consulting Partner · 22 May 2018Strategic engagement with Wilson Sonsini Goodrich and Rosati (WSGR) effective May 22, 2018. Wilson Sonsini is the premier legal advisor to technology and life sciences companies worldwide. Services include corporate law and governance, public and private offerings, M&A, intellectual property litigation, and technology licensing transactions.
• Peridot CorporationcoreImplementation/ SI/ Consulting PartnerStrategic Partner for complete end-to-end precision manufacturing and clean room assembly services. Peridot Corporation is producing pre-production test devices for Heron devices in conjunction with TransMed7's Zero5 technology.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Argon Medical Devices: Argon Medical offers a portfolio of biopsy devices (including the BioPince and SuperCore needles) and vascular intervention products. Its dual presence in biopsy and peripheral vascular mirrors TransMed7's cross-platform ambitions across Cardinal/Heron and Corsair.
• Cook Medical: Cook Medical manufactures a broad portfolio of biopsy needles (e.g., Quick-Core, FNA needles) used across liver, kidney, thyroid, and soft tissue indications. Its product scope and minimally invasive biopsy focus directly overlap with TransMed7's Cardinal and Heron platforms.
• Merit Medical Systems: Merit Medical offers breast biopsy needle markers (CorPac) and core needle biopsy products in the same minimally invasive biopsy space as TransMed7. The company is a direct peer in breast biopsy localization and soft tissue biopsy tools.
• Becton, Dickinson (BD): BD acquired C.R. Bard's biopsy portfolio (including the Max-Core and Mission core needle biopsy devices) and competes across soft tissue, breast, and specialty biopsy indications. BD's breast and soft tissue biopsy devices directly overlap with TransMed7's SpeedBird, Concorde, and Cardinal platforms.
• Hologic: Hologic is the dominant player in breast biopsy with the ATEC, Eviva, and Celero product lines for stereotactic, ultrasound-guided, and MRI-guided breast biopsy. It directly competes with TransMed7's SpeedBird and Concorde platforms targeting the same breast health use cases.
• Mammotome (Danaher/Leica Biosystems): Mammotome is a focused breast biopsy franchise under Danaher, offering vacuum-assisted and core needle biopsy systems (e.g., Mammotome Revolve, Elite). It competes head-to-head with TransMed7's SpeedBird and Concorde platforms in breast health biopsy.
• Cardiovascular Systems (CSI, Abbott): CSI (acquired by Abbott in 2023) is a leading atherectomy company with Diamondback 360 systems for peripheral and coronary disease. It directly competes with TransMed7's Corsair platform for chronic total occlusions.

Emerging players

• Avinger: Avinger develops catheter-based vascular intervention devices (Pantheris, Tigereye) for PAD. It is highly comparable to TransMed7's Corsair platform and was founded by John B. Simpson, who is also a strategic advisor to TransMed7, creating a direct lineage and technology overlap.

Broad incumbents

• Abbott Vascular: Abbott is a major player in vascular intervention following its acquisition of CSI, and operates broadly across coronary and peripheral vascular devices. It competes across TransMed7's TransVascular Dynamics (TVDI) cardiovascular roadmap via the Diamondback atherectomy line.
• Medtronic: Medtronic is a global leader in cardiovascular intervention (atherectomy, stents, balloons) and biopsy through its legacy Covidien portfolio. It serves as a broad incumbent competitor across TransMed7's Corsair and adjacent vascular platforms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCENoCU1UqTYiActuteUupXw
• LinkedInca.linkedin.com/company/transmed7

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TransMed7